| Secondary | Number of Prescriptions of OAD by Each Renal Impairment (RI) Stages | This outcome observes number of index dates for each class of OAD as per RI classes. RI classes were defined based on eGFR values. Results observed were based on index dates used for comparing drugs between the classes. | All index dates computed from patients with eGFR data, included in the study were considered for this analysis. Some patients were prescribed for more than one study drug and thus we can observe more number of index dates than number of patients. | Posted | | Number | | Prescriptions | | Within 6 months from index date | | | | ID | Title | Description |
|---|
| OG000 | Group G1 | The group 1 (G1) contains patients (prescribed for OADs) with renal function stage as normal. Normal renal function stage is defined based on serum creatinine value for males between 0.6 milligram per deciLitre and 1.2 milligram per deciLitre and that for females is between 0.4 milligram per deciLitre and 0.9 milligram per deciLitre. | | OG001 | Group G2 | The group 2 (G2) contains patients (prescribed for OADs) with renal function stage as mild. Mild renal function stage is defined based on serum creatinine value for males between 1.2 milligram per deciLitre and 1.4 milligram per deciLitre and that for females is between 0.9 milligram per deciLitre and 1.2 milligram per deciLitre. | | OG002 | Group G3 | The group 3 (G3) contains patients (prescribed for OADs) with renal function stage as moderate. Moderate renal function stage is defined based on serum creatinine value for males between 1.4 milligram per deciLitre and 2.4 milligram per deciLitre and that for females is between 1.2 milligram per deciLitre and 2.0 milligram per deciLitre. | | OG003 | Group G4+ | The group 4+ (G4+) contains patients (prescribed for OADs) with renal function stage as severe or end stage kidney disease (ESKD). Severe or ESKD renal function stage is defined based on serum creatinine value greater than 2.4 milligram per deciLitre for males and greater than 2.0 milligram per deciLitre for females. | | OG004 | Total | Total for all participants |
| | Units | Counts |
|---|
| Participants | - OG0003868
- OG00111188
- OG0027776
- OG003
|
| | Title | Denominators | Categories |
|---|
| DPP4 inhibitors | | | Title | Measurements |
|---|
| - OG0001592
- OG0014877
- OG0023566
- OG003
|
|
| |
| Primary | Number of Index Dates | The date at which patients having their first prescription for any study drugs between 1st January 2014 and 30th September 2016 is defined as index date. Results observed were based on index dates used for comparing drugs between the classes. The reported data represent the number of time a prescription was written between 1st January 2014 and 30th September 2016. | All index dates computed from patients included in the study were considered for this analysis. Some patients were prescribed for more than one study drug and thus we can observe more number of index dates than number of patients. | Posted | | Number | | Number of Prescriptions | | From 1st January 2014 to 30th September 2016 (At index date) | | | | ID | Title | Description |
|---|
| OG000 | Oral Antibiotic Drugs | Patients with type 2 diabetes mellitus (T2DM) were treated with oral antibiotic drugs (OAD) such as Dipeptidylpeptidase 4 inhibitors, sulfonylureas, biguanides, thiazolidinediones, α- glucosidase and glinides as per prescription in Japan. |
| |
| Primary | Age (Years) | Age of all patients in years calculated for index dates computed from patients in the database. Analysis was done based on index dates used for comparing drugs between the classes. The reported data represent the number of time a prescription was written between 1st January 2014 and 30th September 2016. | All index dates computed from patients included in the study were considered for this analysis. Some patients were prescribed for more than one study drug and thus we can observe more number of index dates than number of patients. | Posted | | Mean | Standard Deviation | Years | | From 1st January 2014 to 30th September 2016 (At index date) | | | | ID | Title | Description |
|---|
| OG000 | Dipeptidyl-peptidase 4 Inhibitor (DPP4i) | Patients with type 2 diabetes mellitus (T2DM) were treated with oral antibiotic drug (OAD), Dipeptidyl-peptidase 4 inhibitors (DPP4i), as per prescription in Japan. | | OG001 | Biguanides (BG) | Patients with type 2 diabetes mellitus (T2DM) were treated with oral antibiotic drug (OAD), Biguanide (BG), as per prescription in Japan. | | OG002 | Sulfonylurea (SU) | Patients with type 2 diabetes mellitus (T2DM) were treated with oral antibiotic drug (OAD), Sulfonylureas (SU), as per prescription in Japan. |
|
| Primary | Sex (Male/Female) | Gender of all patients observed for index dates computed from patients in the database. Results observed were based on index dates used for comparing drugs between the classes. The reported data represent the number of time a prescription was written between 1st January 2014 and 30th September 2016. | All index dates computed from patients included in the study were considered for this analysis. Some patients were prescribed for more than one study drug and thus we can observe more number of index dates than number of patients. | Posted | | Number | | Participants | | From 1st January 2014 to 30th September 2016 (At index date) | | | | ID | Title | Description |
|---|
| OG000 | Dipeptidyl-peptidase 4 Inhibitor (DPP4i) | Patients with type 2 diabetes mellitus (T2DM) were treated with oral antibiotic drug (OAD), Dipeptidyl-peptidase 4 inhibitors (DPP4i), as per prescription in Japan. | | OG001 | Biguanides (BG) | Patients with type 2 diabetes mellitus (T2DM) were treated with oral antibiotic drug (OAD), Biguanide (BG), as per prescription in Japan. | | OG002 | Sulfonylurea (SU) | Patients with type 2 diabetes mellitus (T2DM) were treated with oral antibiotic drug (OAD), Sulfonylureas (SU), as per prescription in Japan. |
|
| Primary | Estimated Glomerular Filtration Rate (eGFR) | Estimated glomerular filtration rate (eGFR) was calculated based on the age at index date and the latest serum creatinine at index date (or during the observation period) using formula eGFR millilitre/minute/1.73 meter^2 (mL/min/1.73 m^2) = 194 × (Creatinine)^-1.094 × (age in year)^-0.287 (× 0.739 if female). Analysis was done based on index dates used for comparing drugs between the classes. | All index dates computed from patients with eGFR data included in the study were considered for this analysis. Some patients were prescribed for more than one study drug and thus we can observe more number of index dates than number of patients. | Posted | | Mean | Standard Deviation | millilitre/minute/1.73 meter^2 | | Within 6 months from index date | | | | ID | Title | Description |
|---|
| OG000 | Dipeptidyl-peptidase 4 Inhibitor (DPP4i) | Patients with type 2 diabetes mellitus (T2DM) were treated with oral antibiotic drug (OAD), Dipeptidyl-peptidase 4 inhibitors (DPP4i), as per prescription in Japan. | | OG001 | Biguanides (BG) | Patients with type 2 diabetes mellitus (T2DM) were treated with oral antibiotic drug (OAD), Biguanide (BG), as per prescription in Japan. | | OG002 | Sulfonylurea (SU) | |
|
| Primary | Prescription Rate of Each Class in Each eGFR Renal Impairment (RI) Level | Renal impairment (RI) is a common complication in patients with type 2 diabetes mellitus (T2DM). Results observed were based on index dates used for comparing drugs between the classes. | All index dates computed from patients with eGFR data included in the study were considered for this analysis. Some patients were prescribed for more than one study drug and thus we can observe more number of index dates than number of patients. | Posted | | Number | | Participants | | Within 6 months from index date | | | | ID | Title | Description |
|---|
| OG000 | Dipeptidyl-peptidase 4 Inhibitor (DPP4i) | Patients with type 2 diabetes mellitus (T2DM) were treated with oral antibiotic drug (OAD), Dipeptidyl-peptidase 4 inhibitors (DPP4i), as per prescription in Japan. | | OG001 | Biguanides (BG) | Patients with type 2 diabetes mellitus (T2DM) were treated with oral antibiotic drug (OAD), Biguanide (BG), as per prescription in Japan. | | OG002 | Sulfonylurea (SU) | Patients with type 2 diabetes mellitus (T2DM) were treated with oral antibiotic drug (OAD), Sulfonylureas (SU), as per prescription in Japan. | |
|
| Primary | Percentage of Concomitant Medications by OAD Classes | Concomitant medication is the drug prescribed other than drug under study in the OAD class on index date. Results observed were based on index dates used for comparing drugs between the classes. | All index dates computed from patients included in the study were considered for this analysis. Some patients were prescribed for more than one study drug and thus we can observe more number of index dates than number of patients. | Posted | | Number | | Percentage of Prescriptions | | On the index month | | | | ID | Title | Description |
|---|
| OG000 | Dipeptidyl-peptidase 4 Inhibitor (DPP4i) | Patients with type 2 diabetes mellitus (T2DM) were treated with oral antibiotic drug (OAD), Dipeptidyl-peptidase 4 inhibitors (DPP4i), as per prescription in Japan. | | OG001 | Biguanides (BG) | Patients with type 2 diabetes mellitus (T2DM) were treated with oral antibiotic drug (OAD), Biguanide (BG), as per prescription in Japan. | | OG002 | Sulfonylurea (SU) | Patients with type 2 diabetes mellitus (T2DM) were treated with oral antibiotic drug (OAD), Sulfonylureas (SU), as per prescription in Japan. | |
|
| Primary | Percentage of Previous Medications (Premedications) by OAD Classes. | Previous medication is the drug prescribed other than drug under study in the OAD class before index date. Results observed were based on index dates used for comparing drugs between the classes | All index dates computed from patients included in the study were considered for this analysis. Some patients were prescribed for more than one study drug and thus we can observe more number of index dates than number of patients. | Posted | | Number | | Percentage of Prescriptions | | On the index month | | | | ID | Title | Description |
|---|
| OG000 | Dipeptidyl-peptidase 4 Inhibitor (DPP4i) | Patients with type 2 diabetes mellitus (T2DM) were treated with oral antibiotic drug (OAD), Dipeptidyl-peptidase 4 inhibitors (DPP4i), as per prescription in Japan. | | OG001 | Biguanides (BG) | Patients with type 2 diabetes mellitus (T2DM) were treated with oral antibiotic drug (OAD), Biguanide (BG), as per prescription in Japan. | | OG002 | Sulfonylurea (SU) | Patients with type 2 diabetes mellitus (T2DM) were treated with oral antibiotic drug (OAD), Sulfonylureas (SU), as per prescription in Japan. | |
|
| Primary | Percentage of Comorbidities by OAD Classes. | The additional diseases co-occuring, defined by International classification of Diseases, tenth revision (ICD-10) code. Results observed were based on index dates used for comparing drugs between the classes. | All index dates computed from patients included in the study were considered for this analysis. Some patients were prescribed for more than one study drug and thus we can observe more number of index dates than number of patients. | Posted | | Number | | Percentage of Comorbidities | | On the index month | | | | ID | Title | Description |
|---|
| OG000 | Dipeptidyl-peptidase 4 Inhibitor (DPP4i) | Patients with type 2 diabetes mellitus (T2DM) were treated with oral antibiotic drug (OAD), Dipeptidyl-peptidase 4 inhibitors (DPP4i), as per prescription in Japan. | | OG001 | Biguanides (BG) | Patients with type 2 diabetes mellitus (T2DM) were treated with oral antibiotic drug (OAD), Biguanide (BG), as per prescription in Japan. | | OG002 | Sulfonylurea (SU) | Patients with type 2 diabetes mellitus (T2DM) were treated with oral antibiotic drug (OAD), Sulfonylureas (SU), as per prescription in Japan. | |
|